Radiologically Guided Biopsies of mCRPC

NCT02432001 | Completed DMC

• 1 other identifier: 125519
• Study Type: observational
• Target: 256
• Locations: 2 countries
• Sites: 5

Brief Summary

The purpose of this study is to better understand how cancer treatment may affect cancer cells. The research will involve genetic, molecular, cellular, and immunologic experiments using blood and tumor specimens. It is hoped that the information gained from these studies will lead to a greater understanding of castrate-resistant prostate cancer and potentially, improvements in cancer treatment. This is a tissue collection protocol requiring image-guided biopsies of metastatic, castration-resistant prostate cancer (mCRPC). The investigators will focus on enrolling patients with metastatic CRPC who have progressed while receiving novel AR-targeted therapeutics such as abiraterone and enzalutamide. This population of patients was selected because resistance develops relatively rapidly following potent inhibitors of AR activity and the mechanisms of resistance have to be better understood. Without comprehensive analysis of mCRPC tumor, the investigators will never gain a full understanding of the biology driving resistance in human disease and developing rational co-targeting approaches will not be possible.

Conditions

Prostate Cancer

Outcome Measures

Primary Outcomes (1)

• Proportion of mCRPC patients with high androgen receptor activity

  Determined by a gene-expression-based signature for Androgen Receptor activity having a probability of \>0.50

  Up to 2 years

Secondary Outcomes (2)

• Progression Free Survival

  Up to 2 years

• Overall Survival

  Up to 2 years

Study Arms (1)

Image-Guided Biopsies

Image-guided biopsies will be performed at the Dream Team Site enrolling the patient. Lesions will be chosen based upon the strength of the evidence suggesting the presence of metastasis and with the goal of minimizing patient risk. Soft tissue lesions and lesions with documented radiologic progression should be prioritized for biopsy. If the Radiologist in charge of the procedure cannot identify a lesion amenable for biopsy, the patient will be considered a screening failure.

Procedure: Image-Guided Biopsies

Interventions

Image-Guided Biopsies PROCEDURE

Image-Guided Biopsies

Eligibility Criteria

• Age: 18 Years+
• Sex: male
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Prostate Cancer

You may qualify if:

• History of histologically confirmed prostate cancer. Patients without histologically confirmed prostate cancer are eligible if both the treating physician and the study investigator agree that the patient's history is unambiguously indicative of advanced prostate cancer (e.g. high PSA responsive to Androgen Deprivation Therapy.)
• Radiographic evidence of metastatic disease amenable to image-guided biopsy of a metastatic site. Soft-tissue as well as bony metastatic lesions will be considered acceptable. Patients with locally advanced disease only (where the biopsy would be of a prostatic mass) are not eligible. Biopsy of newly emerging radiographic metastases is desired and preferable to the biopsy of previously existing lesions whenever possible.
• Platelets \>75,000/μl within 14 days prior to biopsy
• Prothrombin time (PT) or International Normalized Ratio (INR) and a partial thromboplastin time (PTT) \< 1.5 times the institutional upper limit of normal (ULN) within 14 days prior to biopsy.
• Patients on warfarin, aspirin, or other anti-coagulants are eligible provided they are deemed able to tolerate discontinuation of anti-coagulation for one week prior to the biopsy. Conversion to low molecular weight heparin prior to biopsy is permitted per local standard operating procedures, provided there is agreement regarding the procedure between the treating physician, the interventional radiologist and the PI.
• Castrate levels of testosterone (testosterone \<50n g/dL) within 28 days prior to biopsy.
• Patients with significant congenital or acquired bleeding disorders (eg von Wildebrand's disease, acquired bleeding factor inhibitors) are not eligible.
• If no prior orchiectomy, medical castration therapy must continue while on study.
• Prostate-specific antigen (PSA) level obtained within 28 days prior to biopsy.
• Patients currently on first generation oral anti-androgens (flutamide, bicalutamide, nilutamide) must have progressed after at least 4 weeks of anti-androgen discontinuation.
• Patient's disease is currently progressing (in setting of testosterone \< 50 ng/dl), defined by any of the following criteria:
• PSA Progression: PSA level of at least 2 ng/ml which has risen on at least 2 successive occasions, at least one week apart. If the confirmatory PSA (#3) value is less (i.e., #3b) than the screening PSA (#2) value, then an additional test for rising PSA (#4) will be required to document progression for the purposes of eligibility.
• Soft tissue progression: by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
• Bone scan progression: the appearance of \>=2 new lesions. Symptomatic progression in an area of radiologically evident disease.
• One of the following criteria must be met:

Sponsors & Collaborators

• University of California, San Francisco: lead
• American Association for Cancer Research: collaborator

Study Sites (5)

University of California, Davis

Davis, California, 95616, United States

Location

University of California, Los Angeles

Los Angeles, California, 90095, United States

Location

University of California

San Francisco, California, 94143, United States

Location

Oregon Health & Science University

Portland, Oregon, 97239, United States

Location

University of British Columbia

Vancouver, Canada

Location

Related Publications (1)

• Aggarwal R, Huang J, Alumkal JJ, Zhang L, Feng FY, Thomas GV, Weinstein AS, Friedl V, Zhang C, Witte ON, Lloyd P, Gleave M, Evans CP, Youngren J, Beer TM, Rettig M, Wong CK, True L, Foye A, Playdle D, Ryan CJ, Lara P, Chi KN, Uzunangelov V, Sokolov A, Newton Y, Beltran H, Demichelis F, Rubin MA, Stuart JM, Small EJ. Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. J Clin Oncol. 2018 Aug 20;36(24):2492-2503. doi: 10.1200/JCO.2017.77.6880. Epub 2018 Jul 9.

  PMID: 29985747 DERIVED

MeSH Terms

Conditions

Prostatic Neoplasms

Interventions

Image-Guided Biopsy

Condition Hierarchy (Ancestors)

Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Prostatic Diseases; Male Urogenital Diseases

Intervention Hierarchy (Ancestors)

Biopsy; Cytodiagnosis; Cytological Techniques; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Specimen Handling; Diagnostic Techniques, Surgical; Surgical Procedures, Operative; Investigative Techniques

Study Officials

• Eric Small, MD

  University of California, San Francisco

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 28, 2015
• First Posted: May 1, 2015
• Study Start: February 22, 2013
• Primary Completion: January 1, 2020
• Study Completion: January 1, 2020
• Last Updated: October 8, 2021

Record last verified: 2021-10

Data Sharing

• IPD Sharing: Will not share

Locations

CA (1); US (4)